BioNTech SE share price today

BioNTech SE's share price was $90.70 at the close on 4 November 2026. It has been falling for 6 weeks. That is 6.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $86 and $117, and at that close it sat 16% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today BioNTech SE is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 4 weeks running.

Over the last 7.1 years the share price moved +556% while the S&P 500 moved +159%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

BioNTech SE pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

BioNTech SE is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

BioNTech SE posted a net loss of $821 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $1.1 B. That loss is 777.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost $387 M. 8 of the last 12 reported quarters were loss-making.

Read this profit with care: at −$821 M it is bigger than the quarter's whole revenue of $106 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −806.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

BioNTech SE reported $106 M of revenue in the Jun 2026 quarter, −59.5% on the same quarter a year earlier. Over 4 years it has grown −37.6% a year on average. The last full year, FY25, came in at $2.9 B. The last four reported quarters add to $2.6 B.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $2.9 B, +4.3% on the year before.

Recent pace: the last four quarters grew −24.1% on average, against −37.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −7.9%, against −0.8% a year over the last 8 quarters (rolling over).

BioNTech SE's operating margin was −806.6% in the Jun 2026 quarter, 641.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between −46.7% and 78.2%. The latest quarter is below every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −641.6 percentage points on the year while gross margin changed −62.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 96% of BioNTech SE's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $456 M of operating cash against −$1.1 B of profit. After $175 M of spending on assets, $281 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

BioNTech SE does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $712 M on assets over the last 3 years. Averaged over those years that is 8.3% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $712 M over the last 3 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

BioNTech SE's P/E is 243.9×, near the high end of its own history: higher than 96% of past readings. Its usual P/E (the middle reading) is 6.1×, over 2.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

BioNTech SE's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

BioNTech SE earned a ROE of −6% in FY25. Its return on capital used (ROIC) is 41.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −39.6% net margin and 0.13× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a −39.6% net margin × 0.13× asset turnover × 1.14× leverage (assets divided by equity) ≈ −5.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: −29.9% − 11.4% = −41.3 percentage points. The 11.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The −29.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −26.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

BioNTech SE has total debt of $316 M against shareholder equity of $17.8 B as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

We have no ownership or short-position figures for BioNTech SE, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For BioNTech SE, the Z-score is 7.02. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 7.02 is well clear of the danger zone, so the balance sheet is not the risk here.

32.4 out of 100, rank 25 of 30 in Biotechnology, with 64% of the evidence available.

BioNTech SE scores 32.4 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 25. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 9.2 + 8 + 11.3 + 3.9 = 32.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

BioNTech SE ranks 25 of 30 Biotechnology companies on the 4-Factor Sector Score, with 32.4 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Biotechnology, all 30 compared on one page.

BioNTech SE is the 12th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Roivant Sciences, Incyte Corporation and Insmed Incorporated. Just below it: Alnylam Pharmaceuticals, Inc., Exelixis, Inc. and Ascendis Pharma A/S.

Biotechnology companies close in size

9. Roivant Sciences Ltd. $27.6 billion
10. Incyte Corporation $25 billion
11. Insmed Incorporated $24.1 billion
12. BioNTech SE $22.5 billion
13. Alnylam Pharmaceuticals, Inc. $21.6 billion
14. Exelixis, Inc. $17.8 billion
15. Ascendis Pharma A/S $16.9 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

564. Reliance, Inc. $22.5 billion · Steel
565. Equifax Inc. $22.5 billion · Consulting Services
566. BioNTech SE $22.5 billion
567. Amcor plc $22.4 billion · Packaging & Containers
568. International Flavors & Fragrances Inc. $22.4 billion · Specialty Chemicals

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.